WHO Public Assessment Reports (WHOPARs) published
M
News
Medopharm’s chewable albendazole tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
- NT012 Albendazole Tablets, Chewable 400mg – Medopharm - INDIA
MSN Laboratories’ bedaquiline tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
TB395 Bedaquiline fumarate Tablet 100mg - MSN Lab - INDIA
Active Pharmaceutical Ingredient (API) Prequalified
M
Dihydroartemisinin manufactured by Guilin Pharmaceutical Co., Ltd.
Mylan’s nirmatrelvir + ritonavir tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Guilin’s 120 and 180 mg powder for sol for inj prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
2025 Assessment Sessions for In Vitro Diagnostics
IVD
The In Vitro Diagnostics Assessment Team has established a new assessment model combining assessment sessions and between-assessment session work.
First tafenoquine products prequalified
M
WHO Prequalification Unit (PQT) added the below new products to its prequalified list:
First dispersible rifapentine tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Cadila’s dispersible isoniazid tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Cadila’s dispersible ethambutol tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list :
Active Pharmaceutical Ingredient (API) Prequalified
M
Lamivudine (WHOAPI-428) manufactured by Styrax Life Sciences Pvt Ltd has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.
Public announcement to TB in vitro diagnostics manufacturers, procurement agencies and national TB programmes: Extension of WHO GTB recommendation-based procurement eligibility for TB NAT assays until 31 December 2025
IVD
The World Health Organization (WHO), through its Prequalification Unit and Global Tuberculosis Programme, would like to announce that the transition period for WHO procurement el
Active Pharmaceutical Ingredient (API) Prequalified
M
Rifampicin (WHOAPI-507) manufactured by Macleods Pharmaceuticals Ltd has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.
Macleods’ bedaquiline tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
22nd Invitation to Manufacturers and Suppliers of Medicinal Products for HIV Infections and Related Diseases to Submit an Expression of Interest (EOI) for Product Evaluation to the WHO Prequalification Unit
M
The Invitation to Manufacturers for HIV Infections and Related Diseases to submit an Expression of Interest for Product E
Macleods’ pretomanid tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Revised NTD EOI published
M
On 29 October 2024, the revised 9th NTD EOI, now including Moxidectin, was published.
WHO grants approval for use of Bavarian Nordic’s mpox vaccine in adolescents
V
On 8 October 2024, WHO granted prequalification for the age-extension of the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine for use in adolescents aged 12 to 17 years, expanding its indi
Lupin’s isoniazid/rifapentine tablet prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Recent Highlights
IVD
On 14 October 2024 WHO listed the second mpox IVD under the WHO Emergency Use Listing (EUL) procedure.
Public consultation on proposed revisions to the WHO Prequalification of in vitro diagnostics assessment process
IVD
WHO has identified the need to revise the WHO prequalification processes for IVDs to address the growing need for increased access to quality assured IVDs in low and middle-inco
For Public Consultation: New proposed version of the Guidance on reportable changes to IVDs
IVD
WHO is seeking for public comments on a new proposed version of the Guidance on reportable changes to IVDs (deadline for submission of comments by 15 November 2024).
Active Pharmaceutical Ingredient (API) Prequalified
M
Dolutegravir (sodium) manufactured by Aurore Life Sciences Private Limited has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.
Shanghai Desano’s nirmatrelvir + ritonavir tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Sun Pharmaceutical’s atazanavir/ritonavir tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Two PQT Medicines workshops for manufacturers
M
The PQT Medicines 7th Annual Medicines Quality Workshop for Manufacturers will take place from 23 to 26 September 2024.
Active Pharmaceutical Ingredient (API) Prequalified
M
Molnupiravir manufactured by Aurore Life Sciences Private Limited has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.
Active Pharmaceutical Ingredient (API) Prequalified
M
Tranexamic acid manufactured by Ami Lifesciences Private Limited has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.
Shanghai Fosun’s nirmatrelvir + ritonavir tabl prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Indoco’s chewable albendazole tablets prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list:
Shijiazhuang Lonzeal’s tenofovir disoproxil against hepatitis prequalified
M
WHO Prequalification Unit (PQT) added the below new product to its prequalified list: